Advanced development of a vaccine candidate for staphylococcus aureus infection and colonization.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93022C00057
- Awardee
-
Immunartes, LLC UEI ETMGB9KR3GG4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,363,612
Award facts
- Opportunity
-
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases Pre-Solicitation · 20211 · Posted Feb 8, 2021
- Contract value 44% obligated
-
- $5,363,612.00 Current, with exercised options
- $12,081,410.00 Potential, with all options
- Completion date 88% complete
- Current and potential, with all options
- Funding agency
- Office of Logisitics and Acquisition Operations National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60615, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $657,047 | |
| Other Administrative Action | $0 | |
| Change Order | $210,985 | |
| Other Administrative Action | $187,029 | |
| Exercise an Option | $2,566,543 | |
| Other Administrative Action | $622,929 | |
| Original award | $1,119,079 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $12.081 million cost-plus-fixed-fee definitive contract to Immunartes, LLC for advanced development of a vaccine candidate for Staphylococcus aureus infection and colonization on September 21, 2022.
Immunartes is a woman-owned small business. The contract stems from a Broad Agency Announcement solicited February 8, 2021, seeking proposals for advanced vaccine candidates, therapeutic products, and sequencing-based diagnostics against biothreat agents, antimicrobial-resistant infections, and emerging infectious diseases. Work is performed in Chicago, IL with an ultimate completion date of April 30, 2027.
Service Contract Inventory reporting shows FY2024 labor of 3.6 FTEs and 7,517 contractor hours at a derived government-paid rate of $127.96 per hour. The prime self-performed all reported hours with no subcontractors. Invoiced labor grew year-over-year from $5 thousand in FY2022 (58 hours) to $962 thousand in FY2024, reflecting ramp-up from early-stage development work. The derived hourly rate climbed from $89.81 in FY2022 to $129.71 in FY2023 and held near that level in FY2024, signaling labor-mix escalation as technical effort matured.
Quick answers
Who was awarded contract 75N93022C00057?
75N93022C00057 was awarded to Immunartes, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 21, 2022.
How much is contract 75N93022C00057 worth?
The government has obligated $5,363,612 on 75N93022C00057. Its potential value, with all options, is $12,081,410.
Which agency awarded contract 75N93022C00057?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded 75N93022C00057, with funding from Office of Logisitics and Acquisition Operations (National Institutes of Health).
Was contract 75N93022C00057 competed?
The extent of competition for 75N93022C00057 was full and open competition. The government received 10 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award